❌

Reading view

Promoting Responsible DeepSeek Deployment in Health Care: Scoping Review Comparing Grey and White Literature

Background: The rapid deployment of DeepSeek, an open-source large language model has sparked concerns of its impact on patient outcomes and safety. However, little is known about how DeepSeek is used and regulated in these facilities. Objective: This study aimed to 1) systematically review the characteristics of deployed DeepSeek in the top 100 hospitals in China; and 2) compare performances and risks from hospital disclosure with research evidence. Methods: We performed a scoping review of gray and white literature, collecting data from the top 100 Chinese hospitals. We extracted basic characteristics of DeepSeek, its aim, evaluation approach, performance, risk and hospital regulation. A coding framework was developedcovering LLMs application scenario, evaluation dimension and source of risk. Results: We identified a total of 58 DeepSeek models in 48 out of the top 100 Chinese hospitals as well as 27 studies. We observed deployed DeepSeek mainly intended to assist clinical decision making, such as patient diagnosis and treatment recommendation. However, only 36.2% hospital-deployed models clearly indicated a pre-deployment assessment, 22.4% presented assessment results, and 8.6% identified potential risks and countermeasures. We found poor transparency in hospital reporting, with none presenting evaluation details. Hospitals were likely to report DeepSeek’s higher performance and fewer risks. Conclusions: The irresponsible deployment of DeepSeek in Chinese leading hospitals poses potential risks to patient outcomes and safety. We highlight the urgent need that existing regulations should be expanded to the downstream developers and users and hospitals need to perform a more rigorous validation and transparent reporting.
  •  

Large language models driven neural architecture search for universal and lightweight disease diagnosis on histopathology slide images

npj Digital Medicine, Published online: 18 November 2025; doi:10.1038/s41746-025-02042-x

Large language models driven neural architecture search for universal and lightweight disease diagnosis on histopathology slide images
  •  

Advances in molecular pathology and therapy of non-small cell lung cancer

Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6.

ABSTRACT

Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality. Meanwhile, the journey towards amplifying the breadth and depth of the therapeutic effect requires comprehending and integrating diverse and profound progress. In this review, therefore, we aim to comprehensively present such progress that spans the various aspects of molecular pathology, encompassing elucidations of metastatic mechanisms, identification of therapeutic targets, and dissection of spatial omics. Additionally, we also highlight the numerous small molecule and antibody drugs, encompassing their application alone or in combination, across later-line, frontline, neoadjuvant or adjuvant settings. Then, we elaborate on drug resistance mechanisms, mainly involving targeted therapies and immunotherapies, revealed by our proposed theoretical models to clarify interactions between cancer cells and a variety of non-malignant cells, as well as almost all the biological regulatory pathways. Finally, we outline mechanistic perspectives to pursue innovative treatments of NSCLC, through leveraging artificial intelligence to incorporate the latest insights into the design of finely-tuned, biomarker-driven combination strategies. This review not only provides an overview of the various strategies of how to reshape available armamentarium, but also illustrates an example of clinical translation of how to develop novel targeted drugs, to revolutionize therapeutic landscape for NSCLC.

PMID:40517166 | PMC:PMC12167388 | DOI:10.1038/s41392-025-02243-6

  •  
❌